## Mark Tulchinsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5673157/publications.pdf

Version: 2024-02-01

95 papers

2,199 citations

257357 24 h-index 243529 44 g-index

95 all docs 95
docs citations

95 times ranked 2342 citing authors

#	Article	IF	CITATIONS
1	Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 461-468.	3.3	16
2	Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan. Endocrine, 2021, 73, 633-640.	1.1	3
3	The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. Endocrine, 2021, 74, 332-339.	1.1	7
4	The American College of Nuclear Medicine Guidance on Operating Procedures for a Nuclear Medicine Facility During COVID-19 Pandemic. Clinical Nuclear Medicine, 2021, 46, 571-574.	0.7	18
5	Thyroid Lobectomy for T1b-T2 Papillary Thyroid Cancer with High-Risk Features. Journal of the American College of Surgeons, 2020, 230, 136-144.	0.2	18
6	Response to the letter to the editor "18F-FDG-PET/CT indication in patients affected by differentiated thyroid cancer with elevated serum thyroglobulin and negative whole-body scanning after therapy with 131l― European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2952-2953.	3.3	0
7	Incidental CT Findings Suspicious for COVID-19–Associated Pneumonia on Nuclear Medicine Examinations. Clinical Nuclear Medicine, 2020, 45, 531-533.	0.7	30
8	Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2020, 61, 375-396.	2.8	21
9	Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer. International Journal of Cancer, 2020, 147, 2345-2354.	2.3	7
10	Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer. Current Pharmaceutical Design, 2020, 26, 3812-3827.	0.9	8
11	Uptake Within Achilles Tendon on Posttherapy Radioiodine Whole-Body Scan Related to Gouty Tophus. Clinical Nuclear Medicine, 2020, 45, e370-e372.	0.7	2
12	EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2514-2525.	3.3	99
13	Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism. JAMA Internal Medicine, 2019, 179, 1034.	2.6	125
14	Visual Diagnosis: Melena in a 13-month-old Girl. Pediatrics in Review, 2019, 40, e18-e21.	0.2	0
15	Spotlight on the Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism is Keeping the Highest Risk From Antithyroid Drugs in the Blind Spot. Clinical Nuclear Medicine, 2019, 44, 789-791.	0.7	26
16	Selective history of radioactive iodine in medicine: Inexactitudes no longer. European Journal of Surgical Oncology, 2019, 45, 711-712.	0.5	1
17	Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy. Journal of Nuclear Medicine, 2018, 59, 723-725.	2.8	20
18	Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms. Journal of Clinical Oncology, 2018, 36, 1887-1888.	0.8	12

#	Article	IF	CITATIONS
19	ACR–ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 909-917.	0.7	47
20	Detecting Intestinal Malrotation on Hepatobiliary Scintigraphy. Clinical Nuclear Medicine, 2018, 43, 289-293.	0.7	2
21	The SNMMI and EANM practice guideline for renal scintigraphy in adults. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2218-2228.	3.3	41
22	Re: Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a). Clinical Nuclear Medicine, 2018, 43, 630-630.	0.7	1
23	Current Status of Ventilation-Perfusion Scintigraphy for Suspected Pulmonary Embolism. American Journal of Roentgenology, 2017, 208, 489-494.	1.0	27
24	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 863.1-863.	2.8	5
25	Normal Gallbladder Ejection Fraction Occurring Unexpectedly Obviates Need for Sincalide Stimulation. Clinical Nuclear Medicine, 2017, 42, 394-396.	0.7	0
26	Arteriography for Lower Gastrointestinal Hemorrhage. JAMA Surgery, 2017, 152, 209.	2.2	0
27	Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. Journal of Nuclear Medicine, 2017, 58, 1530-1530.	2.8	2
28	Applications of Ventilation-Perfusion Scintigraphy in Surgical Management of Chronic Obstructive Lung Disease and Cancer. Seminars in Nuclear Medicine, 2017, 47, 671-679.	2.5	7
29	Informed consent for low-risk thyroid cancer. International Journal of Endocrine Oncology, 2016, 3, 131-142.	0.4	6
30	Papillary thyroid microcarcinoma and active surveillance. Lancet Diabetes and Endocrinology, the, 2016, 4, 974.	5.5	3
31	In Comparing Diagnostic Accuracy of Ultrasound and Hepatobiliary Scintigraphy for Acute Cholecystitis, It Is Only Fair that Both Tests Are Done and Interpreted at aAComparable Skill Level. Journal of Emergency Medicine, 2016, 50, 507-508.	0.3	0
32	Oral Cholecystagogue Cholescintigraphy. Clinical Nuclear Medicine, 2015, 40, 796-798.	0.7	7
33	Radiopharmaceutical Options for the Ventilation Part of Ventilation-Perfusion Scintigraphy Performed for the Indication of Pulmonary Embolism. Clinical Nuclear Medicine, 2015, 40, 553-558.	0.7	6
34	Bacillus Calmette-Guerin Injections for Melanoma Immunotherapy. Clinical Nuclear Medicine, 2015, 40, 368-369.	0.7	6
35	ACR Appropriateness Criteria® Right Lower Quadrant Painâ€"Suspected Appendicitis. Ultrasound Quarterly, 2015, 31, 85-91.	0.3	130
36	Standing Prone Positioning in Establishing Causality Between Matched Ventilation-Perfusion Defects and Pleural Effusion. Clinical Nuclear Medicine, 2015, 40, 88-90.	0.7	0

#	Article	IF	CITATIONS
37	The SNMMI Procedure Standard/EANM Practice Guideline for Gastrointestinal Bleeding Scintigraphy 2.0. Journal of Nuclear Medicine Technology, 2014, 42, 308-317.	0.4	49
38	ACR Appropriateness Criteria Right Upper Quadrant Pain. Journal of the American College of Radiology, 2014, 11, 316-322.	0.9	98
39	SPECT/CT Helps in Localization and Guiding Management of Small Bowel Gastrointestinal Hemorrhage. Clinical Nuclear Medicine, 2014, 39, 94-96.	0.7	17
40	Nuclear Medicine Tests for Acute Gastrointestinal Conditions. Seminars in Nuclear Medicine, 2013, 43, 88-101.	2.5	19
41	PET/CT in Primary Hepatic Lymphoma With Hepatic Vein Thrombus That Extended Into the Inferior Vena Cava. Clinical Nuclear Medicine, 2013, 38, 153-156.	0.7	5
42	SPECT/CT Unequivocally Depicts Dilated Cystic Duct Sign on Hepatobiliary Scintigraphy in Acute Cholecystitis. Clinical Nuclear Medicine, 2013, 38, 149-152.	0.7	3
43	Subcutaneous Injection of 99mTc-Pertechnetate for Neonatal Thyroid Scintigraphy. Clinical Nuclear Medicine, 2013, 38, 1015-1018.	0.7	1
44	Marginal zone lymphoma: old, new, targeted, and epigenetic therapies. Therapeutic Advances in Hematology, 2012, 3, 275-290.	1.1	30
45	Utility of Diagnostic Whole-Body Iodine Scanning in High-Risk Differentiated Thyroid Carcinoma. Journal of Nuclear Medicine, 2012, 53, 661-662.	2.8	0
46	SNM Practice Guideline for Parathyroid Scintigraphy 4.0. Journal of Nuclear Medicine Technology, 2012, 40, 111-118.	0.4	136
47	Pericatheter Leak in a Peritoneal Dialysis Patient. Clinical Nuclear Medicine, 2012, 37, 625-628.	0.7	7
48	Cholecystokinin-Cholescintigraphy in Adults. Clinical Nuclear Medicine, 2012, 37, 63-70.	0.7	30
49	False-Positive Bone Metastases on PET/CT Secondary to Sarcoidosis in a Patient With Rectal Cancer. Clinical Nuclear Medicine, 2012, 37, 307-310.	0.7	11
50	Mebrofenin Clearance Rate for Liver Function Testing. Clinical Nuclear Medicine, 2012, 37, 644-648.	0.7	2
51	Lymphoma in a Case of Shwachman-Diamond Syndrome. Clinical Nuclear Medicine, 2012, 37, 74-76.	0.7	7
52	Liver Function Testing with Nuclear Medicine Techniques Is Coming of Age. Seminars in Nuclear Medicine, 2012, 42, 124-137.	2.5	46
53	Hepatobiliary Scintigraphy in Acute Cholecystitis. Seminars in Nuclear Medicine, 2012, 42, 84-100.	2.5	32
54	Isolated Cardiac Metastasis From Papillary Thyroid Cancer: Prolonged Survival with Late Diagnosis Related to Inadequate Positron Emission Tomography Preparation. Thyroid, 2012, 22, 443-444.	2.4	5

#	Article	IF	CITATIONS
55	ACR Appropriateness Criteria $\hat{A}^{\otimes}$ Suspected Upper Extremity Deep Vein Thrombosis. Journal of the American College of Radiology, 2012, 9, 613-619.	0.9	20
56	ACR Appropriateness Criteria® Pretreatment Staging of Colorectal Cancer. Journal of the American College of Radiology, 2012, 9, 775-781.	0.9	80
57	Cholecystokinin-Cholescintigraphy in Adults: Consensus Recommendations of an Interdisciplinary Panel. Clinical Gastroenterology and Hepatology, 2011, 9, 376-384.	2.4	47
58	ACR Appropriateness Criteria® Right Lower Quadrant Painâ€"Suspected Appendicitis. Journal of the American College of Radiology, 2011, 8, 749-755.	0.9	184
59	Longer Tc-99m-Mebrofenin Labeling-to-Administration Time Results in Scintigraphic Underestimation of Liver Function. Clinical Nuclear Medicine, 2011, 36, 1079-1085.	0.7	4
60	False-Positive PET/CT for Lymphoma Recurrence Secondary to Langerhans Cell Histiocytosis. Clinical Nuclear Medicine, 2011, 36, 717-719.	0.7	2
61	Unexpected Gallbladder Emptying From Visual Stimulation. Clinical Nuclear Medicine, 2011, 36, 1065-1068.	0.7	1
62	Sincalide-Stimulated Cholescintigraphy: A Multicenter Investigation to Determine Optimal Infusion Methodology and Gallbladder Ejection Fraction Normal Values. Journal of Nuclear Medicine, 2010, 51, 277-281.	2.8	62
63	SNM Practice Guideline for Hepatobiliary Scintigraphy 4.0. Journal of Nuclear Medicine Technology, 2010, 38, 210-218.	0.4	98
64	The SNM Practice Guideline on Hepatobiliary Scintigraphy. Journal of Nuclear Medicine, 2010, 51, 1825-1825.	2.8	12
65	Sincalide infusion parameters: key information in a biliary dyskinesia clinical study. American Surgeon, 2010, 76, 1304-5.	0.4	1
66	<sup>123</sup> lâ€ <i>m</i> lBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatric Blood and Cancer, 2009, 52, 784-790.	0.8	111
67	F-18 FDG PET/CT in Primary Gastric Small Cell Carcinoma. Clinical Nuclear Medicine, 2009, 34, 44-47.	0.7	3
68	Small Bowel Metastasis From Lung Cancer Detected on FDG PET/CT. Clinical Nuclear Medicine, 2009, 34, 446-448.	0.7	14
69	Radioguided Reoperative Thyroid and Parathyroid Surgery. Otolaryngologic Clinics of North America, 2008, 41, 1185-1198.	0.5	9
70	Lower Gastrointestinal Bleeding Diagnosed by Red Blood Cell Scintigraphy in a Patient With a Left Ventricular Assist Device. Clinical Nuclear Medicine, 2008, 33, 856-858.	0.7	9
71	Increased F-18 FDG Uptake in Resolving Atraumatic Bilateral Adrenal Hemorrhage (Hematoma) on PET/CT. Clinical Nuclear Medicine, 2008, 33, 651-653.	0.7	25
72	Matched Ventilation-perfusion Defect From A Pleural Effusion. Clinical Nuclear Medicine, 2008, 33, 407-410.	0.7	1

#	Article	IF	CITATIONS
73	Diagnostic Features of Fibrodysplasia (Myositis) Ossificans Progressiva on Bone Scan. Clinical Nuclear Medicine, 2007, 32, 616-619.	0.7	11
74	Meckel's Scan: Pitfall in Patients With Active Small Bowel Bleeding. Clinical Nuclear Medicine, 2006, 31, 814-816.	0.7	10
75	Alternatives for Measuring Endogenous Adrenocortical Activity in Asthmatics Treated with Inhaled Corticosteroids. Endocrine Research, 2005, 31, 245-258.	0.6	4
76	Leukocyte receptor-binding radiopharmaceuticals for infection and inflammation scintigraphy. Journal of Nuclear Medicine, 2005, 46, 718-21.	2.8	6
77	Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertility and Sterility, 1999, 72, 21-25.	0.5	94
78	Bowel Compression on the Gallbladder Mimicking a Gallstone on Cholescintigraphy. Clinical Nuclear Medicine, 1997, 22, 709-710.	0.7	1
79	Transmission Image Aids in Diagnosis of Hiatus Hernia During Gastric Emptying Study. Clinical Nuclear Medicine, 1996, 21, 999-1000.	0.7	3
80	Diagnosis of Urinoma by MAG3 Scintigraphy in a Renal Transplant Patient. Clinical Nuclear Medicine, 1995, 20, 80-81.	0.7	13
81	False Appearance of Urinary Stasis on Tc-99m MAG3 Renal Scan Secondary to Vicarious Tracer Concentration in the Gallbladder. Clinical Nuclear Medicine, 1995, 20, 836-838.	0.7	2
82	Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1330-1338.	2.2	62
83	Progressive Accumulation of Activity on Scrotal Scintigraphy in Early Incarcerated Inguinal Hernia. Clinical Nuclear Medicine, 1994, 19, 1019-1020.	0.7	3
84	Intraperitoneal Distribution Imaging Prior to Chromic Phosphate (P-32) Therapy in Ovarian Cancer Patients. Clinical Nuclear Medicine, 1994, 19, 43-48.	0.7	4
85	Tracheobronchial Aspiration Observed During Ventilation Perfusion Lung Scanning. Clinical Nuclear Medicine, 1994, 19, 240-242.	0.7	0
86	Tc-99m MAG3 Renography in Renal Vein Thrombosis Secondary to Finnish-Type Congenital Nephrotic Syndrome. Clinical Nuclear Medicine, 1994, 19, 888-891.	0.7	7
87	Scintigraphic evaluation of pediatric urinary tract infection. Seminars in Nuclear Medicine, 1993, 23, 199-218.	2.5	51
88	Color- Doppler- Directed Echocardiographie T echnique for the Evaluation of Left Ventricular Diastolic Filling: Validation by Radionuclide Angiography. American Journal of Noninvasive Cardiology, 1993, 7, 1-6.	0.1	1
89	Clinical Application of Magnetic Resonance Imaging of the Heart and Great Vessels. Angiology, 1992, 43, 709-719.	0.8	8
90	Urinary Fibrinopeptide a in Evaluation of Patients with Suspected Acute Pulmonary Embolism. Chest, 1991, 100, 394-398.	0.4	4

#	Article	IF	CITATIONS
91	Quantitation of Differential Renal Function with Tc-99m MDP. Clinical Nuclear Medicine, 1991, 16, 649-651.	0.7	1
92	Urinary fibrinopeptide A levels in ischemic heart disease. Journal of the American College of Cardiology, 1989, 14, 597-603.	1.2	25
93	Success of Prolonged Therapy with the Somatostatin Analog, Octreotide Acetate, in Recalcitrant Enterocutaneous Fistulas. Digestive Surgery, 1989, 6, 142-145.	0.6	4
94	Applied hepatobiliary scintigraphy in acute cholecystitis., 0,, 21-30.		1
95	Applied hepatobiliary scintigraphy in chronic gallbladder diseases. , 0, , 17-25.		0